Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Innate Pharma FY EPS $(0.10) Up From $(0.75) YoY, Sales $66.35M Up From $58.87M YoY

Author: Benzinga Newsdesk | March 21, 2024 02:07am

Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.10) per share. This is a 87.2 percent increase over losses of $(0.75) per share from the same period last year. The company reported $66.35 million in sales this quarter. This is a 12.71 percent increase over sales of $58.87 million the same period last year.

Cash position of €102.3 million1 as of December 31, 2023 excluding the €15m from Sanofi, anticipated cash runway to end of 2025

Posted In: IPHA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist